KR20160068960A - 면역요법을 위한 다클론성 감마 델타 t 세포 - Google Patents
면역요법을 위한 다클론성 감마 델타 t 세포 Download PDFInfo
- Publication number
- KR20160068960A KR20160068960A KR1020167012774A KR20167012774A KR20160068960A KR 20160068960 A KR20160068960 A KR 20160068960A KR 1020167012774 A KR1020167012774 A KR 1020167012774A KR 20167012774 A KR20167012774 A KR 20167012774A KR 20160068960 A KR20160068960 A KR 20160068960A
- Authority
- KR
- South Korea
- Prior art keywords
- cells
- cell
- aapc
- composition
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 title claims abstract description 78
- 238000009169 immunotherapy Methods 0.000 title description 11
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 313
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 107
- 238000000034 method Methods 0.000 claims abstract description 86
- 208000036142 Viral infection Diseases 0.000 claims abstract description 12
- 230000009385 viral infection Effects 0.000 claims abstract description 11
- 208000035143 Bacterial infection Diseases 0.000 claims abstract description 7
- 208000022362 bacterial infectious disease Diseases 0.000 claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 229
- 239000000203 mixture Substances 0.000 claims description 63
- 108010002350 Interleukin-2 Proteins 0.000 claims description 45
- 102000000588 Interleukin-2 Human genes 0.000 claims description 45
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 44
- 102100030704 Interleukin-21 Human genes 0.000 claims description 41
- 108010074108 interleukin-21 Proteins 0.000 claims description 41
- 201000011510 cancer Diseases 0.000 claims description 37
- 238000012258 culturing Methods 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 210000004700 fetal blood Anatomy 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 21
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 claims description 19
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims description 19
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 17
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 17
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 15
- 206010033128 Ovarian cancer Diseases 0.000 claims description 15
- 239000011886 peripheral blood Substances 0.000 claims description 14
- 210000005259 peripheral blood Anatomy 0.000 claims description 14
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 13
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 13
- 201000002528 pancreatic cancer Diseases 0.000 claims description 13
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 13
- 241000701022 Cytomegalovirus Species 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 11
- 206010009944 Colon cancer Diseases 0.000 claims description 10
- 230000000735 allogeneic effect Effects 0.000 claims description 10
- 230000001413 cellular effect Effects 0.000 claims description 10
- 210000000822 natural killer cell Anatomy 0.000 claims description 10
- 208000029742 colonic neoplasm Diseases 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 7
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 7
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 7
- 239000011325 microbead Substances 0.000 claims description 7
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 6
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims description 6
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims description 5
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims description 5
- 229940127174 UCHT1 Drugs 0.000 claims description 5
- 210000002203 alpha-beta t lymphocyte Anatomy 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 claims description 4
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 claims description 4
- 206010040047 Sepsis Diseases 0.000 claims description 4
- 230000000779 depleting effect Effects 0.000 claims description 4
- 206010029260 Neuroblastoma Diseases 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 238000011275 oncology therapy Methods 0.000 claims description 3
- 230000003442 weekly effect Effects 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 230000009261 transgenic effect Effects 0.000 claims description 2
- 208000025321 B-lymphoblastic leukemia/lymphoma Diseases 0.000 claims 2
- 230000002458 infectious effect Effects 0.000 claims 2
- 208000017426 precursor B-cell acute lymphoblastic leukemia Diseases 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 abstract description 4
- 230000000840 anti-viral effect Effects 0.000 abstract description 3
- 230000009257 reactivity Effects 0.000 abstract description 3
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 74
- 108091008874 T cell receptors Proteins 0.000 description 73
- 206010057190 Respiratory tract infections Diseases 0.000 description 57
- 239000000427 antigen Substances 0.000 description 51
- 108091007433 antigens Proteins 0.000 description 51
- 102000036639 antigens Human genes 0.000 description 51
- 230000014509 gene expression Effects 0.000 description 51
- 102000004127 Cytokines Human genes 0.000 description 43
- 108090000695 Cytokines Proteins 0.000 description 43
- 238000002474 experimental method Methods 0.000 description 34
- 230000035755 proliferation Effects 0.000 description 30
- 230000003211 malignant effect Effects 0.000 description 28
- 210000004881 tumor cell Anatomy 0.000 description 28
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 27
- 238000003501 co-culture Methods 0.000 description 22
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 21
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 21
- 239000000523 sample Substances 0.000 description 21
- 108700010039 chimeric receptor Proteins 0.000 description 20
- 108020004999 messenger RNA Proteins 0.000 description 19
- 239000012636 effector Substances 0.000 description 18
- 230000006870 function Effects 0.000 description 18
- 102100027207 CD27 antigen Human genes 0.000 description 17
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 17
- 238000000338 in vitro Methods 0.000 description 16
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 108700028369 Alleles Proteins 0.000 description 14
- 102000005962 receptors Human genes 0.000 description 14
- 201000009030 Carcinoma Diseases 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 13
- 210000003719 b-lymphocyte Anatomy 0.000 description 13
- 150000007523 nucleic acids Chemical class 0.000 description 13
- 239000013598 vector Substances 0.000 description 13
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 12
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 12
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 12
- 230000004913 activation Effects 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 11
- 230000006037 cell lysis Effects 0.000 description 11
- 230000003834 intracellular effect Effects 0.000 description 11
- 201000001441 melanoma Diseases 0.000 description 11
- -1 CLA Proteins 0.000 description 10
- 208000009956 adenocarcinoma Diseases 0.000 description 10
- 238000002955 isolation Methods 0.000 description 10
- 241000894007 species Species 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 102100038077 CD226 antigen Human genes 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 9
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 description 9
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 9
- 108090000172 Interleukin-15 Proteins 0.000 description 9
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 9
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 9
- 206010039491 Sarcoma Diseases 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 108010062214 gamma-delta T-Cell Antigen Receptors Proteins 0.000 description 9
- 102000011778 gamma-delta T-Cell Antigen Receptors Human genes 0.000 description 9
- 230000004068 intracellular signaling Effects 0.000 description 9
- 208000032839 leukemia Diseases 0.000 description 9
- 230000015654 memory Effects 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 8
- 240000007019 Oxalis corniculata Species 0.000 description 8
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 230000009089 cytolysis Effects 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 108010054624 red fluorescent protein Proteins 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 description 7
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 7
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 102000003812 Interleukin-15 Human genes 0.000 description 7
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 108700041286 delta Proteins 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 230000011664 signaling Effects 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 238000007619 statistical method Methods 0.000 description 7
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 206010025323 Lymphomas Diseases 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 238000000692 Student's t-test Methods 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000004186 co-expression Effects 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 230000036210 malignancy Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 102000006306 Antigen Receptors Human genes 0.000 description 5
- 108010083359 Antigen Receptors Proteins 0.000 description 5
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 5
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 5
- 230000006052 T cell proliferation Effects 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 201000005787 hematologic cancer Diseases 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 102100040840 C-type lectin domain family 7 member A Human genes 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 4
- 108010012236 Chemokines Proteins 0.000 description 4
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 description 4
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 4
- 102100033467 L-selectin Human genes 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 4
- 108091061960 Naked DNA Proteins 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 4
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 238000002659 cell therapy Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 4
- 108010025838 dectin 1 Proteins 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 230000002489 hematologic effect Effects 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 238000010606 normalization Methods 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
- 241000228212 Aspergillus Species 0.000 description 3
- 206010003571 Astrocytoma Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 3
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 3
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 3
- 102000000013 Chemokine CCL3 Human genes 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 108090000331 Firefly luciferases Proteins 0.000 description 3
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 3
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 3
- 101001055145 Homo sapiens Interleukin-2 receptor subunit beta Proteins 0.000 description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 3
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 3
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 3
- 102100026879 Interleukin-2 receptor subunit beta Human genes 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 3
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 3
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000005809 anti-tumor immunity Effects 0.000 description 3
- 230000006023 anti-tumor response Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 108091008034 costimulatory receptors Proteins 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 210000003298 dental enamel Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000010362 genome editing Methods 0.000 description 3
- 238000011194 good manufacturing practice Methods 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 3
- 239000000833 heterodimer Substances 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000010212 intracellular staining Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 230000005298 paramagnetic effect Effects 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000012384 transportation and delivery Methods 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 3
- 229960004276 zoledronic acid Drugs 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 2
- 201000003076 Angiosarcoma Diseases 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 206010004593 Bile duct cancer Diseases 0.000 description 2
- 241000588807 Bordetella Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 2
- 108700012434 CCL3 Proteins 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 2
- 208000005243 Chondrosarcoma Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 208000005234 Granulosa Cell Tumor Diseases 0.000 description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 description 2
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 description 2
- 108091010847 High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 description 2
- 101000603882 Homo sapiens Nuclear receptor subfamily 1 group I member 3 Proteins 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 2
- 201000000053 blastoma Diseases 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- 208000035269 cancer or benign tumor Diseases 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000011018 current good manufacturing practice Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 201000008184 embryoma Diseases 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 201000010225 mixed cell type cancer Diseases 0.000 description 2
- 208000029638 mixed neoplasm Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 108010089193 pattern recognition receptors Proteins 0.000 description 2
- 102000007863 pattern recognition receptors Human genes 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 230000005026 transcription initiation Effects 0.000 description 2
- 244000052613 viral pathogen Species 0.000 description 2
- 102100025601 60S ribosomal protein L27 Human genes 0.000 description 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- 208000016557 Acute basophilic leukemia Diseases 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000007690 Brenner tumor Diseases 0.000 description 1
- 206010073258 Brenner tumour Diseases 0.000 description 1
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 101710155856 C-C motif chemokine 3 Proteins 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 108010084313 CD58 Antigens Proteins 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 206010050337 Cerumen impaction Diseases 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 1
- 206010008583 Chloroma Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 201000005171 Cystadenoma Diseases 0.000 description 1
- 102100026234 Cytokine receptor common subunit gamma Human genes 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102100027700 DNA-directed RNA polymerase I subunit RPA2 Human genes 0.000 description 1
- 102100021429 DNA-directed RNA polymerase II subunit RPB1 Human genes 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 102100020743 Dipeptidase 1 Human genes 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 108010075944 Erythropoietin Receptors Proteins 0.000 description 1
- 102100036509 Erythropoietin receptor Human genes 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 101710191461 F420-dependent glucose-6-phosphate dehydrogenase Proteins 0.000 description 1
- DSIFMINXCSHZPQ-UHFFFAOYSA-M FUN-1 Chemical compound [I-].S1C2=CC=CC=C2[N+](C)=C1C=C(C1=CC=CC=C11)C=C(Cl)N1C1=CC=CC=C1 DSIFMINXCSHZPQ-UHFFFAOYSA-M 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 208000004463 Follicular Adenocarcinoma Diseases 0.000 description 1
- 208000007569 Giant Cell Tumors Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 101710155861 Glucose-6-phosphate 1-dehydrogenase Proteins 0.000 description 1
- 102100035172 Glucose-6-phosphate 1-dehydrogenase Human genes 0.000 description 1
- 101710174622 Glucose-6-phosphate 1-dehydrogenase, chloroplastic Proteins 0.000 description 1
- 101710137456 Glucose-6-phosphate 1-dehydrogenase, cytoplasmic isoform Proteins 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 208000002291 Histiocytic Sarcoma Diseases 0.000 description 1
- 241000228402 Histoplasma Species 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000719728 Homo sapiens 60S ribosomal protein L27 Proteins 0.000 description 1
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
- 101100166600 Homo sapiens CD28 gene Proteins 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101001055227 Homo sapiens Cytokine receptor common subunit gamma Proteins 0.000 description 1
- 101000650600 Homo sapiens DNA-directed RNA polymerase I subunit RPA2 Proteins 0.000 description 1
- 101001106401 Homo sapiens DNA-directed RNA polymerase II subunit RPB1 Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000594698 Homo sapiens Ornithine decarboxylase antizyme 1 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101001081189 Homo sapiens Rho GTPase-activating protein 45 Proteins 0.000 description 1
- 101000946850 Homo sapiens T-lymphocyte activation antigen CD86 Proteins 0.000 description 1
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 description 1
- 241000829111 Human polyomavirus 1 Species 0.000 description 1
- 201000001916 Hypochondriasis Diseases 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000701460 JC polyomavirus Species 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 208000000265 Lobular Carcinoma Diseases 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- 102000007557 Melanoma-Specific Antigens Human genes 0.000 description 1
- 108010071463 Melanoma-Specific Antigens Proteins 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 102100023123 Mucin-16 Human genes 0.000 description 1
- 206010057269 Mucoepidermoid carcinoma Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010029488 Nodular melanoma Diseases 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 102100036199 Ornithine decarboxylase antizyme 1 Human genes 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 241000233870 Pneumocystis Species 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000017414 Precursor T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 101710156592 Putative TATA-binding protein pB263R Proteins 0.000 description 1
- 101150081636 RPS13 gene Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 102100027748 Rho GTPase-activating protein 45 Human genes 0.000 description 1
- 241000316848 Rhodococcus <scale insect> Species 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 208000009574 Skin Appendage Carcinoma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- 241001279361 Stachybotrys Species 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 102100034924 T-lymphocyte activation antigen CD86 Human genes 0.000 description 1
- 101710145783 TATA-box-binding protein Proteins 0.000 description 1
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 102000005918 Ubiquitin Thiolesterase Human genes 0.000 description 1
- 108010005656 Ubiquitin Thiolesterase Proteins 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 102000040856 WT1 Human genes 0.000 description 1
- 108700020467 WT1 Proteins 0.000 description 1
- 101150084041 WT1 gene Proteins 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 241000021375 Xenogenes Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- SAZUGELZHZOXHB-UHFFFAOYSA-N acecarbromal Chemical compound CCC(Br)(CC)C(=O)NC(=O)NC(C)=O SAZUGELZHZOXHB-UHFFFAOYSA-N 0.000 description 1
- NFXWJYUDIOHFAW-UHFFFAOYSA-N acetic acid;tetradecanoic acid Chemical compound CC(O)=O.CCCCCCCCCCCCCC(O)=O NFXWJYUDIOHFAW-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006786 activation induced cell death Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 208000002517 adenoid cystic carcinoma Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 108010087408 alpha-beta T-Cell Antigen Receptors Proteins 0.000 description 1
- 102000006707 alpha-beta T-Cell Antigen Receptors Human genes 0.000 description 1
- 206010065867 alveolar rhabdomyosarcoma Diseases 0.000 description 1
- 101150073130 ampR gene Proteins 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000000578 anorexic effect Effects 0.000 description 1
- 201000007436 apocrine adenocarcinoma Diseases 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 201000005008 bacterial sepsis Diseases 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 201000007551 basophilic adenocarcinoma Diseases 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 208000007047 blue nevus Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000010983 breast ductal carcinoma Diseases 0.000 description 1
- 201000003714 breast lobular carcinoma Diseases 0.000 description 1
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000002939 cerumen Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 201000005217 chondroblastoma Diseases 0.000 description 1
- 210000004252 chorionic villi Anatomy 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 231100000409 cytocidal Toxicity 0.000 description 1
- 230000000445 cytocidal effect Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 238000007822 cytometric assay Methods 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000009409 embryonal rhabdomyosarcoma Diseases 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 230000005294 ferromagnetic effect Effects 0.000 description 1
- 201000008825 fibrosarcoma of bone Diseases 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 201000008298 histiocytosis Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000031261 interleukin-10 production Effects 0.000 description 1
- 102000008616 interleukin-15 receptor activity proteins Human genes 0.000 description 1
- 108040002039 interleukin-15 receptor activity proteins Proteins 0.000 description 1
- 108091008582 intracellular receptors Proteins 0.000 description 1
- 102000027411 intracellular receptors Human genes 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 238000007443 liposuction Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 201000006812 malignant histiocytosis Diseases 0.000 description 1
- 206010061526 malignant mesenchymoma Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 208000000516 mast-cell leukemia Diseases 0.000 description 1
- 201000008749 mast-cell sarcoma Diseases 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002991 molded plastic Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- 201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
- 208000004707 mucinous cystadenoma Diseases 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 201000005987 myeloid sarcoma Diseases 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000025426 neoplasm of thorax Diseases 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 201000000032 nodular malignant melanoma Diseases 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 201000009804 nonencapsulated sclerosing carcinoma Diseases 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 201000010302 ovarian serous cystadenocarcinoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 208000000793 papillary cystadenoma Diseases 0.000 description 1
- 201000001494 papillary transitional carcinoma Diseases 0.000 description 1
- 208000031101 papillary transitional cell carcinoma Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 201000002628 peritoneum cancer Diseases 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 208000031223 plasma cell leukemia Diseases 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000008520 protoplasmic astrocytoma Diseases 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000022120 response to tumor cell Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 108010038196 saccharide-binding proteins Proteins 0.000 description 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
- 201000003804 salivary gland carcinoma Diseases 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 208000005893 serous cystadenoma Diseases 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 208000028210 stromal sarcoma Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 150000004044 tetrasaccharides Chemical class 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 201000003957 thoracic cancer Diseases 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000026308 thyroid gland diffuse sclerosing papillary carcinoma Diseases 0.000 description 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
- 208000015191 thyroid gland papillary and follicular carcinoma Diseases 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/54—Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Developmental Biology & Embryology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Mycology (AREA)
- Materials For Medical Uses (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361895626P | 2013-10-25 | 2013-10-25 | |
| US61/895,626 | 2013-10-25 | ||
| PCT/US2014/062191 WO2015061694A2 (en) | 2013-10-25 | 2014-10-24 | Polyclonal gamma delta t cells for immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160068960A true KR20160068960A (ko) | 2016-06-15 |
Family
ID=52993756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167012774A Ceased KR20160068960A (ko) | 2013-10-25 | 2014-10-24 | 면역요법을 위한 다클론성 감마 델타 t 세포 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9907820B2 (enExample) |
| EP (1) | EP3060059A4 (enExample) |
| JP (1) | JP2016539929A (enExample) |
| KR (1) | KR20160068960A (enExample) |
| CN (1) | CN105848484A (enExample) |
| AU (2) | AU2014339926B2 (enExample) |
| CA (1) | CA2926859A1 (enExample) |
| WO (1) | WO2015061694A2 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2601896T3 (es) | 2004-11-24 | 2017-02-16 | Fred Hutchinson Cancer Research Center | Procedimientos de uso de la IL-21 en la inmunoterapia adoptiva y la identificación de antígenos tumorales |
| EP3974520A1 (en) | 2013-05-14 | 2022-03-30 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| WO2014190273A1 (en) | 2013-05-24 | 2014-11-27 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
| CA3190002A1 (en) | 2014-02-14 | 2015-08-20 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors and methods of making |
| GB201506423D0 (en) | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
| WO2016073629A1 (en) | 2014-11-05 | 2016-05-12 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) to selectively target protein complexes |
| IL252131B2 (en) * | 2014-11-17 | 2023-04-01 | Adicet Bio Inc | Transgenic gamma delta T cells |
| US20220280564A1 (en) * | 2014-11-21 | 2022-09-08 | Immatics US, Inc. | Methods for expanding t cells for the treatment of cancer and related malignancies |
| EP3804741A3 (en) | 2015-02-24 | 2021-07-14 | Board of Regents, The University of Texas System | Selection methods for genetically-modified t cells |
| CA2977818A1 (en) | 2015-03-11 | 2016-09-15 | Board Of Regents, The University Of Texas System | Transposase polypeptides and uses thereof |
| GB201507368D0 (en) | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
| WO2016179684A1 (en) * | 2015-05-11 | 2016-11-17 | University Health Network | Method for expansion of double negative regulatory t cells |
| MX386334B (es) * | 2015-05-12 | 2025-03-18 | Memorial Sloan Kettering Cancer Center | Cèlulas t y sus usos en el tratamiento de trastornos linfoproliferativos asociados al virus de epstein-barr. |
| US11166983B2 (en) * | 2015-06-09 | 2021-11-09 | Lymphact—Lymphocyte Activation Technologies, S.A. | Methods for the production of TCRγδ+ T cells |
| DK3307875T3 (da) * | 2015-06-09 | 2022-03-21 | Lymphact Lymphocyte Activation Tech S A | Fremgangsmåder til fremstilling af tcr-gamma-delta+-t-celler |
| CN105112370B (zh) * | 2015-08-25 | 2019-02-05 | 杭州优善生物科技有限公司 | 一种体外刺激外周血γδT细胞高效增殖的方法及其应用 |
| EP3340997B1 (en) * | 2015-08-25 | 2024-02-14 | The UAB Research Foundation | Methods for stem cell transplantation |
| KR20180042449A (ko) | 2015-09-15 | 2018-04-25 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | T 세포 수용체(tcr) 결합 항체 및 이의 용도 |
| CN105624107B (zh) * | 2015-09-21 | 2020-06-12 | 杭州优善生物科技有限公司 | 一种多种淋巴细胞亚群的扩增方法及其应用 |
| EP3368075B1 (en) | 2015-10-27 | 2020-01-29 | Board of Regents, The University of Texas System | Chimeric antigen receptor molecules and uses thereof |
| CA3003077A1 (en) | 2015-10-30 | 2017-05-04 | King's College London | Expansion of non-haematopoietic tissue-resident .gamma.delta. t cells and uses of these cells |
| MX2018013864A (es) | 2016-05-12 | 2019-06-10 | Adicet Bio Inc | Métodos para la expansión selectiva de poblaciones de células t gama y composicicones de estas. |
| WO2018081784A1 (en) * | 2016-10-31 | 2018-05-03 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Artificial antigen presenting cells for expanding immune cells for immunotherapy |
| TWI788307B (zh) * | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| CN110494558B (zh) * | 2017-02-08 | 2023-07-07 | 新加坡科技研究局 | Gamma delta t细胞和增强其杀肿瘤活性的方法 |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| GB201707048D0 (en) * | 2017-05-03 | 2017-06-14 | King S College London | Expansion of gamma delta cells, compositions, and methods of use thereof |
| CN109337872B (zh) * | 2017-07-27 | 2023-06-23 | 上海细胞治疗研究院 | 高效扩增car-t细胞的人工抗原递呈细胞及其用途 |
| US20200297871A1 (en) * | 2017-09-15 | 2020-09-24 | King's College London | Compositions and methods for enhancing gamma delta t cells in the gut |
| CN107794269A (zh) * | 2017-09-30 | 2018-03-13 | 成都美杰赛尔生物科技有限公司 | 促进基因编辑t细胞活化及扩增的生物膜、制法及应用 |
| TWI687227B (zh) * | 2017-10-03 | 2020-03-11 | 生倍科技股份有限公司 | 用於t細胞免疫療法之組合及其用途 |
| JP7227630B2 (ja) | 2017-10-12 | 2023-02-22 | マックマスター ユニバーシティー | Ｙ１８２ｔ突然変異を有するｔ細胞－抗原カプラおよびその方法ならびに使用 |
| MX2020005005A (es) | 2017-11-15 | 2020-08-27 | Adicet Bio Inc | Métodos para la expansión selectiva de poblaciones de células t gamma delta delta 3 y composiciones de estas. |
| CN108588023B (zh) * | 2018-05-09 | 2020-02-14 | 河北森朗生物科技有限公司 | 一种生产嵌合抗原受体修饰的γδT细胞的方法 |
| US10640562B2 (en) | 2018-07-17 | 2020-05-05 | Mcmaster University | T cell-antigen coupler with various construct optimizations |
| BR112021005184A8 (pt) * | 2018-09-19 | 2022-08-16 | Lava Therapeutics B V | Imunoglobulina cd1d de dupla ação |
| KR20210069665A (ko) * | 2018-09-27 | 2021-06-11 | 포스포감, 인크. | 동종이계 감마/델타-t 세포의 확장 및 사용을 위한 방법 및 조성물 |
| MX2021003744A (es) * | 2018-10-01 | 2021-06-23 | Adicet Bio Inc | Composiciones y métodos relacionados con linfocitos t gamma delta modificados y no modificados para el tratamiento de tumores sólidos. |
| JP7687952B2 (ja) | 2018-10-01 | 2025-06-03 | アディセット セラピューティクス， インク． | 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法 |
| GB201818243D0 (en) | 2018-11-08 | 2018-12-26 | Gammadelta Therapeutics Ltd | Methods for isolating and expanding cells |
| AU2020225597A1 (en) * | 2019-02-24 | 2021-10-07 | Gamida-Cell Ltd. | Method of homing and retention of gammadelta T cells for generating cell compositions for use in therapy |
| AU2020267504A1 (en) * | 2019-05-08 | 2021-12-02 | Janssen Biotech, Inc. | Materials and methods for modulating T cell mediated immunity |
| WO2021016652A1 (en) * | 2019-07-29 | 2021-02-04 | The University Of Melbourne | METHODS AND COMPOSITIONS FOR MONITORING, TREATING AND PREVENTING CMV INFECTION OR GRAFT REJECTION USING γδ T-CELLS |
| MX2022002747A (es) | 2019-09-10 | 2022-04-06 | Obsidian Therapeutics Inc | Proteinas de fusion de ca2-il15 para regulacion ajustable. |
| AU2021225817A1 (en) * | 2020-02-24 | 2022-10-20 | Immatics US, Inc. | Methods for expanding T cells for the treatment of cancer and related malignancies |
| CN111647070B (zh) * | 2020-06-17 | 2022-06-03 | 深圳豪石生物科技有限公司 | T细胞受体或其抗原结合片段及应用 |
| AU2021324767A1 (en) * | 2020-08-12 | 2023-04-13 | University Of Central Florida Research Foundation, Inc. | Methods and compositions for stimulating gamma delta T cells |
| EP4347660A4 (en) | 2021-06-01 | 2025-06-04 | Triumvira Immunologics USA, Inc. | CLAUDIN-18.2 T-CELL ANTIGEN COUPLER AND USES THEREOF |
| CA3235971A1 (en) * | 2021-10-20 | 2023-04-27 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods and materials for expanding tumor infiltrating gamma-delta t cells |
| EP4433068A4 (en) * | 2021-11-18 | 2025-11-12 | Univ Minnesota | LARGE-SCALE MULTIPLICATION OF MODIFIED HUMAN GAMMA T LYMPHOCYTES |
| EP4183871A1 (en) | 2021-11-23 | 2023-05-24 | Université d'Aix-Marseille | Process for preparing a composition comprising a combined cell population |
| TW202341971A (zh) | 2022-02-16 | 2023-11-01 | 法商普萊歐塞拉公司 | 使用car細胞及s1p受體調節劑之治療方法 |
| PE20242341A1 (es) * | 2022-04-04 | 2024-12-12 | Gammadelta Therapeutics Ltd | Blindaje genetico novedoso |
| CN114645022B (zh) * | 2022-05-13 | 2022-09-02 | 首都医科大学宣武医院 | 靶向CD5的CAR-γ δ T细胞及其制备方法与应用 |
| WO2025046256A1 (en) | 2023-08-31 | 2025-03-06 | Universite D'aix-Marseille | Process for preparing a composition comprising a combined cell population |
| CN118064364B (zh) * | 2024-04-19 | 2024-07-05 | 赛德特生物制药有限公司 | 一种γδT细胞的制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997032970A1 (en) | 1996-03-04 | 1997-09-12 | Targeted Genetics Corporation | Modified rapid expansion methods ('modified-rem') for in vitro propagation of t lymphocytes |
| IL144339A0 (en) * | 1999-01-28 | 2002-05-23 | Palmetto Health Alliance | A cell line containing gamma delta lymphocytes and pharmaceutical compositions containing the same |
| AU2003202908A1 (en) | 2002-01-03 | 2003-07-24 | The Trustees Of The University Of Pennsylvania | Activation and expansion of t-cells using an engineered multivalent signaling platform |
| CA2568344C (en) * | 2004-05-27 | 2016-01-19 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| CA2665568C (en) | 2006-10-04 | 2018-01-09 | Janssen Pharmaceutica, N.V. | Preparation of inactivated artificial antigen presenting cells and their use in cell therapies |
| ES2538817T3 (es) | 2008-07-01 | 2015-06-24 | Medinet Co., Ltd. | Método para la inducción simultánea de CTL y células gamma delta T |
| CA2736851A1 (en) * | 2008-09-11 | 2010-03-18 | Lung-Ji Chang | System and method for producing t cells |
| PT2710123T (pt) * | 2011-05-19 | 2017-10-13 | Inst De Medicina Molecular | Linha celular de linfócitos compreendendo células t gama-delta, método de composição e produção resultante dos mesmos |
| US20120321666A1 (en) | 2011-05-23 | 2012-12-20 | Cooper Laurence J N | T cell therapy for b cell lymphoma |
| WO2013074916A1 (en) * | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
-
2014
- 2014-10-24 CN CN201480063632.0A patent/CN105848484A/zh active Pending
- 2014-10-24 CA CA2926859A patent/CA2926859A1/en not_active Abandoned
- 2014-10-24 US US15/031,610 patent/US9907820B2/en not_active Expired - Fee Related
- 2014-10-24 JP JP2016525990A patent/JP2016539929A/ja active Pending
- 2014-10-24 EP EP14854993.4A patent/EP3060059A4/en not_active Withdrawn
- 2014-10-24 AU AU2014339926A patent/AU2014339926B2/en not_active Ceased
- 2014-10-24 WO PCT/US2014/062191 patent/WO2015061694A2/en not_active Ceased
- 2014-10-24 KR KR1020167012774A patent/KR20160068960A/ko not_active Ceased
-
2018
- 2018-01-16 US US15/872,354 patent/US20180200299A1/en not_active Abandoned
- 2018-04-30 AU AU2018202976A patent/AU2018202976B2/en not_active Ceased
-
2020
- 2020-12-18 US US17/127,627 patent/US20210187028A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014339926A1 (en) | 2016-04-28 |
| EP3060059A4 (en) | 2017-11-01 |
| US20160256487A1 (en) | 2016-09-08 |
| CN105848484A (zh) | 2016-08-10 |
| AU2018202976A1 (en) | 2018-05-31 |
| WO2015061694A3 (en) | 2015-06-18 |
| WO2015061694A2 (en) | 2015-04-30 |
| AU2018202976B2 (en) | 2020-10-29 |
| JP2016539929A (ja) | 2016-12-22 |
| AU2014339926B2 (en) | 2018-02-08 |
| US9907820B2 (en) | 2018-03-06 |
| US20210187028A1 (en) | 2021-06-24 |
| CA2926859A1 (en) | 2015-04-30 |
| US20180200299A1 (en) | 2018-07-19 |
| EP3060059A2 (en) | 2016-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018202976B2 (en) | Polyclonal gamma delta t cells for immunotherapy | |
| US11344577B2 (en) | Car+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA | |
| AU2019311290B2 (en) | Therapeutic preparations of gamma-delta T cells and Natural Killer cells and methods for manufacture and use | |
| US12227555B2 (en) | Use of gene editing to generate universal TCR re-directed t cells for adoptive immunotherapy | |
| JP2023063429A (ja) | 改変キメラ抗原受容体（ｃａｒ）ｔ細胞のヒト応用 | |
| CN111247242A (zh) | 嵌合抗原受体(CARs)、组合物及其使用方法 | |
| RS66264B1 (sr) | Genska terapija | |
| TW202402798A (zh) | 對新抗原具特異性之結合蛋白與工程化細胞及其用途 | |
| CN115916963A (zh) | 白血病来源的经修饰细胞用于增强过继性细胞治疗的效力的离体用途 | |
| JP2025102823A (ja) | 臨床的に意義のあるｅｇｆｒ変異型タンパク質との交差反応性を有する高親和性キメラ抗原受容体（ｃａｒ）を含む、組成物および方法 | |
| CA3240846A1 (en) | Cd5 modified cells comprising chimeric antigen receptors (cars) for treatment of solid tumors | |
| JP2024502170A (ja) | 癌のための改良された養子細胞移植療法 | |
| WO2025214498A1 (en) | Composition and method of cellular immunotherapy | |
| US20240325535A1 (en) | Compositions and methods comprising car t cells comprising prdm1 and/or nr4a3 knockout | |
| HK40127569A (zh) | 用於肿瘤治疗的car修饰剂的产生 | |
| HK40105961A (zh) | 评估和治疗t细胞功能障碍的组合物和方法 | |
| HK40055874B (zh) | γ-δ T细胞和自然杀伤细胞的治疗制剂以及制造和使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20160516 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20191022 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20210220 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20211006 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20210220 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| E601 | Decision to refuse application | ||
| E801 | Decision on dismissal of amendment | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20220117 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20210220 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| PE0801 | Dismissal of amendment |
Patent event code: PE08012E01D Comment text: Decision on Dismissal of Amendment Patent event date: 20220117 Patent event code: PE08011R01I Comment text: Amendment to Specification, etc. Patent event date: 20211228 Patent event code: PE08011R01I Comment text: Amendment to Specification, etc. Patent event date: 20210819 Patent event code: PE08011R01I Comment text: Amendment to Specification, etc. Patent event date: 20191022 |